Drug Testing

Providers Seek More Sensible Drug Testing During Coronavirus Crisis
Public health risk is forcing addiction treatment programs to rethink their typical approaches to patient drug testing at this time.
Rx Summit Spotlight: Dual Focus on Opioids and Stimulants Grows Urgent
A speaker at this spring's Rx Drug Abuse & Heroin Summit discusses the latest national data on emerging drug threats, highlighting the need to focus on stimulant trends.
Drug Test Results Signal Great Concern Over Methamphetamine Trend
A newly published Millennium Health report suggests that worrisome methamphetamine trends need to be on the entire field's radar.
Physicians Struggle to Manage Dual Issues of Pain and Addiction
A report released today by Quest Diagnostics and the Center on Addiction shows some inconsistencies between physician perspectives and patient behaviors regarding prescription drug use.
Fentanyl Has Become a Prominent Danger for Stimulant Users
A Millennium Health analysis adds to the evidence that fentanyl now has a dangerously prominent presence in the cocaine and methamphetamine supply.
Kratom Included in Areas of Concern in Trends Report
Millennium Health data show widespread increases in positive drug test rates for the controversial substance kratom.
Presence of Other Drugs in Patients Using Buprenorphine Raises Concern
A trends report from Millennium Health indicates a frequent presence of other substances, particularly marijuana, in patients prescribed buprenorphine for opioid dependence.
Pioneering Effort to Help Impaired Workers Gets Expansion
Belden, Inc.'s often-cited effort to assist job applicants who fail a pre-employment drug test will be expanded to two additional company locations.
Drug Testing Early in Treatment Can Enhance Care
A study reveals that drug testing can serve as an important guide to outpatient treatment at stages where patients may be reluctant to self-report use.
Treatment retention improved with injectable naltrexone over oral version
An open-label study found that opioid-dependent individuals stayed in treatment longer and had fewer opioid-positive drug screens when on injectable naltrexone, as opposed to the oral formulation of the drug.
Red flags on benzodiazepines, gabapentin in drug misuse report
Quest Diagnostics' analysis of drug monitoring data finds several areas of potential concern, including for patients being treated in specialty substance use settings.
Back to Top